Taisho Pharmaceutical Holdings Co Ltd - Company Profile
Powered by 
All the data and insights you need on Taisho Pharmaceutical Holdings Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Taisho Pharmaceutical Holdings Co Ltd Strategy Report
- Understand Taisho Pharmaceutical Holdings Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Taisho Pharmaceutical Holdings Co Ltd (Taisho Pharmaceutical), a subsidiary of Otemon Co Ltd, develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company’s self-medication products comprise over the counter (OTC) products, quasi-drugs and health food products. Its prescription pharmaceuticals portfolio includes ethical drugs in the fields of infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases. Taisho Pharmaceutical provide its products under Pabron, Lipovitan D, Riup, Livita, Colac, Zosyn, Clarith, Palux, Edirol, Geninax, and Lorcam brand names. The company operates through its subsidiaries located in the Philippines, Indonesia, Malaysia, Thailand, Vietnam, China, Singapore, Taiwan and the US. Taisho Pharmaceutical is headquartered in Toshima-ku, Tokyo, Japan.
Headquarters
Japan
Address
3-24-1, Takada, Toshima-Ku, Tokyo, 170-8655
Website
www.taisho-holdings.co.jp
Telephone
81 3 39852020
No of Employees
8,784
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4581 (TYO)
Revenue (2022)
$2.2B
12.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
44.8%
(2022 vs 2021)
Market Cap*
$4.8B
Net Profit Margin (2022)
XYZ
28.8%
(2022 vs 2021)
* As of and is in US$
Taisho Pharmaceutical Holdings Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Self-Medication Products | Counterpain |
| Prescription Pharmaceutical Products | Tempra |
| Lipovitan Series | Hapacol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In August, the company approved to manufacture and markets Nanozora 30mg autoinjectors for S.C. Injection in Japan. |
| 2023 | Contracts/Agreements | In June, the company enters into a strategic collaboration with Biolinq for an exclusive license agreement in Japan. |
| 2023 | New Products/Services | In April, the company announced to launch a drink Lipovitan D Premium. |
Competitor Comparison
| Key Parameters | Taisho Pharmaceutical Holdings Co Ltd | Otsuka Holdings Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Mitsubishi Tanabe Pharma Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Toshima-Ku | Minato-Ku | Chuo-Ku | Chuo-Ku | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 8,784 | 34,388 | 14,484 | 17,435 | 6,697 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Akira Uehara | Chief Executive Officer; Director | Executive Board | 2015 | - |
| Shigeru Uehara | Director; Executive Vice President | Executive Board | 2015 | - |
| Tetsu Watanabe | Director; Managing Executive Officer | Executive Board | 2016 | - |
| Osamu Kitatani | Director; Executive Officer | Executive Board | 2021 | - |
| Jun Kuroda | Director | Executive Board | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward